Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03314181
Title A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications

multiple myeloma

Therapies

Bortezomib + Daratumumab + Dexamethasone + Venetoclax

Daratumumab + Dexamethasone

Daratumumab + Dexamethasone + Venetoclax

Age Groups: adult | senior
Covered Countries USA | FRA | DEU | CAN


No variant requirements are available.